These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24524420)

  • 1. Elimination of human T cell leukemia virus type-1-infected cells by neutralizing and antibody-dependent cellular cytotoxicity-inducing antibodies against human t cell leukemia virus type-1 envelope gp46.
    Tanaka Y; Takahashi Y; Tanaka R; Kodama A; Fujii H; Hasegawa A; Kannagi M; Ansari AA; Saito M
    AIDS Res Hum Retroviruses; 2014 Jun; 30(6):542-52. PubMed ID: 24524420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A protective role of HTLV-1 gp46-specific neutralizing and antibody-dependent cellular cytotoxicity-inducing antibodies in progression to adult T-cell leukemia (ATL).
    Tanaka Y; Tanaka R; Imaizumi N; Mizuguchi M; Takahashi Y; Hayashi M; Miyagi T; Uchihara J; Ohshiro K; Masuzaki H; Fukushima T
    Front Immunol; 2022; 13():921606. PubMed ID: 36177005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neutralizing function of the anti-HTLV-1 antibody is essential in preventing in vivo transmission of HTLV-1 to human T cells in NOD-SCID/γcnull (NOG) mice.
    Saito M; Tanaka R; Fujii H; Kodama A; Takahashi Y; Matsuzaki T; Takashima H; Tanaka Y
    Retrovirology; 2014 Aug; 11():74. PubMed ID: 25163482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.
    Kuroki M; Nakamura M; Itoyama Y; Tanaka Y; Shiraki H; Baba E; Esaki T; Tatsumoto T; Nagafuchi S; Nakano S
    J Immunol; 1992 Aug; 149(3):940-8. PubMed ID: 1378869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
    Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
    J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
    Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
    J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-dependent cell-mediated cytotoxicity (ADCC) in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP).
    Fujihara K; Itoyama Y; Yu F; Kubo C; Goto I
    J Neurol Sci; 1996 Oct; 142(1-2):65-9. PubMed ID: 8902722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process.
    Kuo CW; Mirsaliotis A; Brighty DW
    J Immunol; 2011 Jul; 187(1):361-71. PubMed ID: 21646298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1.
    Jacobson S; Reuben JS; Streilein RD; Palker TJ
    J Immunol; 1991 Feb; 146(4):1155-62. PubMed ID: 1704032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathogenetic significance of HTLV-I infection and immune surveillance in HAM].
    Fujihara K
    Rinsho Shinkeigaku; 1999 Jan; 39(1):21-3. PubMed ID: 10377790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
    Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
    J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Tax antibody levels in asymptomatic carriers, oligosymptomatic carriers, patients with rheumatologic disease or with HAM/TSP do not correlate with HTLV-1 proviral load.
    de Souza JG; da Fonseca FG; Martins ML; Martins CP; de Carvalho LD; Coelho-dos-Reis JG; Carneiro-Proietti AB; Martins-Filho OA; Barbosa-Stancioli EF;
    J Clin Virol; 2011 Jan; 50(1):13-8. PubMed ID: 20951636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Potential of an Anti-HTLV-I gp46 Neutralizing Monoclonal Antibody (LAT-27) for Passive Immunization against Both Horizontal and Mother-to-Child Vertical Infection with Human T Cell Leukemia Virus Type-I.
    Fujii H; Shimizu M; Miyagi T; Kunihiro M; Tanaka R; Takahashi Y; Tanaka Y
    Viruses; 2016 Feb; 8(2):. PubMed ID: 26848684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement-dependent cytotoxic antibodies to human T lymphotropic virus type I (HTLV-I)-infected cells in the sera of HTLV-I-infected individuals.
    Plotnicky-Gilquin H; Afani A; Vernant JC; Desgranges C
    Clin Exp Immunol; 1996 Jul; 105(1):39-45. PubMed ID: 8697633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between antibody-dependent cell-mediated cytotoxicity due to anti-HTLV-1 and negative signal of major histocompatibility complex class I antigens on adult T-cell leukemia cell lines.
    Komatsu F; Tamiya H
    Oncol Res; 1998; 10(2):59-67. PubMed ID: 9666513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal molecular mimicry in immune-mediated neurologic disease.
    Levin MC; Krichavsky M; Berk J; Foley S; Rosenfeld M; Dalmau J; Chang G; Posner JB; Jacobson S
    Ann Neurol; 1998 Jul; 44(1):87-98. PubMed ID: 9667596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervicovaginal synthesis of IgG antibodies to the immunodominant 175-199 domain of the surface glycoprotein gp46 of human T-cell leukemia virus type I.
    Bélec L; Georges-Courbot MC; Georges A; Mohamed AS; Londos-Gagliardi D; Hallouin MC; Hocini H; Guillemain B
    J Med Virol; 1996 Sep; 50(1):42-9. PubMed ID: 8890040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer activity and antibody-dependent cellular cytotoxicity in patients with adult T-cell leukemia.
    Uno H; Kawano K; Matsuoka H; Tsuda K
    Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):730-9. PubMed ID: 2618548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
    Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
    Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different B-cell responses to human T-cell lymphotropic virus type I (HTLV-I) envelope synthetic peptides in HTLV-I-infected individuals.
    Ida H; Kurata A; Eguchi K; Kawakami A; Migita K; Fukuda T; Nakamura T; Kusumoto Y; Berzofsky JA; Nagataki S
    J Clin Immunol; 1991 May; 11(3):143-51. PubMed ID: 1890164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.